<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305927</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD083113</org_study_id>
    <nct_id>NCT02305927</nct_id>
  </id_info>
  <brief_title>Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health</brief_title>
  <acronym>ToV5</acronym>
  <official_title>Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wafaie Fawzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Management and Development for Health (MDH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess the effect of maternal vitamin D3 (cholecalciferol)
      supplementation on maternal HIV progression, small-for-gestational age infants, and infant
      stunting at 12 months postpartum for HIV-infected Tanzanian pregnant women who are receiving
      highly active antiretroviral therapy (HAART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled trial of maternal vitamin D3
      (cholecalciferol) supplementation starting in the second trimester (12-27 weeks gestation)
      and continuing until 12 months postpartum among HIV-infected Tanzanian pregnant women who are
      receiving HAART. Eligible individuals are randomized to receive a) a vitamin D3 regimen
      consisting 3,000 IU of vitamin D3 taken orally once daily starting in the second trimester
      and continuing until 12 months postpartum or b) a placebo regimen taken orally once daily
      starting in the second trimester and continuing until 12 months postpartum. Mothers will be
      followed at study visits during pregnancy and mother/infant pairs will attend study visits
      from birth until trial discharge at 12 months postpartum.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants experiencing maternal HIV progression</measure>
    <time_frame>Second Trimester until 12 months post partum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of small-for-gestational age infants</measure>
    <time_frame>Birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of stunted infants (height-for-age z-score &lt; -2)</measure>
    <time_frame>12 months postpartum (1 year of age)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2300</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol)</intervention_name>
    <description>Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum</description>
    <arm_group_label>Vitamin D3 (cholecalciferol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥18 years old

          -  HIV-positive

          -  Receiving HAART

          -  Pregnant and of 12-27 weeks gestation (Second Trimester)

          -  Calcium levels in the normal physiologic range (≤2.6 mmol/L)

        Exclusion Criteria:

          -  Enrolled in any other clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wafaie W Fawzi, MBBS, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher R Sudfeld, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim P Manji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Management and Development for Health (MDH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Management and Development for Health (MDH)</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Sudfeld CR, Manji KP, Duggan CP, Aboud S, Muhihi A, Sando DM, Al-Beity FMA, Wang M, Fawzi WW. Effect of maternal vitamin D(3) supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial. Trials. 2017 Sep 4;18(1):411. doi: 10.1186/s13063-017-2157-3.</citation>
    <PMID>28870263</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health</investigator_affiliation>
    <investigator_full_name>Wafaie Fawzi</investigator_full_name>
    <investigator_title>Professor of Nutrition, Epidemiology, and Global Health</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Pregnant women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

